SPDL1 and gastric cancer: Elevated baseline sPD-L1 also associated with shorter PFS (median: 1.7 vs 2.1 months) and OS (median: 4.1 vs 8.9 months) in gastric cancer patients treated with anti-PD-1 [79], and with shorter OS (median: 24.6 vs > 40 months) and lower objective response rate (ORR) in metastatic renal cell carcinoma patients treated with nivolumab [80].